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Abstract 
Purpose: Posterior fossa brain tumours (PFT) and their treatment in young children are often 
associated with subsequent cognitive impairment. However, reported follow-up periods 
rarely exceed 10 years. This study reports very long-term cognitive consequences of 
surviving an early childhood PFT. 
Methods: 62 adult survivors of a PFT, ascertained from a national register, diagnosed before 
5 years of age, and a sibling control, received a single IQ assessment an average of 32 years 
(range 18-53) after initial diagnosis, using the Weschler Abbreviated Scale of Intelligence. 
Regression models were fitted to survivor-sibling pair differences on verbal and performance 
IQ (VIQ and PIQ) scores to investigate whether increasing time between PFT diagnosis and 
follow-up IQ assessment contributed to survivor-sibling IQ differences. 
Results: At follow-up, survivors had, on average, VIQ 15 points and PIQ 19 points lower 
than their siblings. There was no significant effect of time since diagnosis on survivor – 
sibling VIQ difference. Survivors who received radiotherapy showed no significant effect of 
time since diagnosis on survivor – sibling PIQ difference. Survivors who did not receive 
radiotherapy demonstrated a trend for it to reduce. 
Conclusions: VIQ and PIQ deficits persist in adulthood, suggesting the effect of a fixed 
injury imposing on cognitive development, rather than an ongoing pathological process. 
Implications for Cancer Survivors: The findings will help parents and others supporting 
survivors of an early life PFT to identify and plan for possible cognitive outcomes, and  
highlight the importance of early interventions to optimize cognitive function during the 
developmental period. 
 
Keywords:   posterior fossa, childhood brain tumour, survivorship, cognition  
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Introduction: 
Posterior fossa brain tumours (PFT) and their treatment in children can be associated with subsequent 
cognitive impairment [1-4]. Rates of survival from childhood brain tumours have been increasing but 
tumour management tends to be more challenging in younger children and it is amongst these 
survivors that greater cognitive morbidity is observed [5-9]. Factors associated with increased risk of 
later cognitive decline include, most powerfully, radiotherapy [10-13].  
Longer periods since diagnosis are associated with more impaired intellectual functioning [7, 9, 10, 
14, 15]. However, whilst many studies have described short- and medium-term cognitive outcomes in 
survivors of a childhood PFT (see reviews by Robinson et al. [3], de Ruiter et al. [10], Nathan et al. 
[16]), few have investigated long-term cognitive outcomes in later adulthood of PFT survivors 
diagnosed in early childhood [3, 6, 9, 11].   
This study reports long-term cognitive consequences of surviving an early childhood PFT. The results 
should be relevant for survivors, their families and their clinicians, and for services supporting adults 
with a history of an early childhood PFT. 
 
Methods: 
Study design 
Adult survivors of a childhood PFT, diagnosed before the age of five years, were identified from the 
UK National Registry of Childhood Tumours (UK NRCT), which holds clinical data going back as 
far as the 1940s. We aimed to recruit a complete as possible sample across England to participate in a 
single face-to-face assessment including an established IQ measure. To provide an approximate 
indication of how pre-morbid intellectual ability may have developed in these survivors if they had 
not had a brain tumour, we measured the IQ of a non-affected sibling of each survivor. This work was 
part of a wider project that examined mental health outcomes in adult survivors of early childhood 
PFT [17]. 
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Eligibility criteria 
Adults aged at least 18 years at follow-up who had been diagnosed with a PFT before the age of 5 
years, between the years 1940 and 1991, were identified from the UK NRCT and recruited through 
their General Practitioners. In the main analyses reported here, the adult survivor group comprised all 
those for whom a sibling provided comparison IQ data (Figure 1). Siblings were recruited through the 
index participants, with one sibling recruited for each index participant. Where more than one sibling 
was available, the one closest in age to the index participant was recruited.  
 
Approvals and Consent 
Approval was given by the Cambridgeshire 2 Research Ethics Committee and UK National 
Information Governance Board. Informed consent was obtained from all individual participants 
included in the study who had capacity to consent. Participants lacking capacity were included where 
agreement was gained from family or carers, as required by the Mental Capacity Act (England and 
Wales) 2005. 
 
Assessments 
IQ was measured using the Wechsler Abbreviated Scale of Intelligence (WASI) [18]. This is a 
standardised, psychometrically robust, brief measure of intelligence assessing verbal knowledge, 
verbal reasoning, visual information processing, and visual perception, through the use of four 
subtests: Vocabulary and Similarities to measure verbal IQ (VIQ), Block Design and Matrix 
Reasoning to measure performance IQ (PIQ) [18]. The WASI correlates highly with the equivalent 
full Wechsler Adult Intelligence Scale (WAIS-III, [19]; WASI and WAIS-III correlations [18]: VIQ 
0.88, PIQ 0.84), but makes fewer demands on participants. 
A structured psychiatric assessment was also undertaken, results from which have been published 
previously [17].   
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Tumour Registry data 
For each survivor, age at diagnosis, sex, tumour type and treatment received were extracted from the 
NRCT. Available treatment details varied between participants, so cranial radiotherapy, chemotherapy 
and surgery descriptions were dichotimised to confirmed use, or not, of the treatment. Tumour types 
were condensed into astrocytoma, medulloblastoma or ‘other’.   
 
Statistical analysis 
The main aim is to investigate whether increasing time since tumour diagnosis affects VIQ and PIQ 
outcomes in adulthood of survivors of an early childhood PFT. We also investigate if the changes 
over time differ for those who had received radiotherapy.  
Univariate group comparisons tested differences between groups of survivors and their siblings using 
Fisher’s exact test and t-tests as appropriate. Subsequently, within the survivors, we investigated 
relationships between VIQ and PIQ, cancer treatment received, age at diagnosis and sex, using 
Fisher’s exact test and t-tests as appropriate. Finally, regression models further investigated 
differences in IQ between survivors and their siblings. 
Odds ratios (ORs) and Pearson’s correlation coefficient (r) are used as measures of effect size. In 
places, Pearson’s r was calculated from t-statistics, as described in Field et al. [20], using a formula 
from Rosenthal and Rubin [21]. Effect sizes are interpreted according to the benchmarks in Cohen 
[22]. 
 
Statistical analysis: Regression modelling 
The difference between survivors’ and their siblings’ VIQ and PIQ scores were analysed using 
generalised additive models (GAMs); these were fitted using the mgcv package (see Wood [23]) in 
the statistical software R. 
In each model, the sibling’s IQ score is included as a covariate to act as a proxy for unmeasured 
confounders (elements of environment, including shared family environment and genetics). We also 
include a quadratic form of the IQ measures as a further covariate in case the relationship with 
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unmeasured confounders is not linear. Both linear and quadratic forms of the sibling measures are 
centered (using a mean of 100). 
Further covariates (levels of categorical variables denoted in parentheses) include: survivor sex; 
sibling sex (same, different); epilepsy (present, absent); (centred) time in years since diagnosis; age in 
months at diagnosis; tumour type (astrocytoma, medulloblastoma, other); radiotherapy (no confirmed 
treatment, confirmed radiotherapy); surgery (no confirmed surgery, confirmed surgery). GAMs allow 
fitting of a penalized regression spline to time since diagnosis, the covariate of primary interest, 
allowing more flexible relationships (rather than a straight line); Supplementary materials present an 
analysis restricted to linear relationships for comparison.  
We consider five interactions (denoted ‘×’): survivor sex × sibling sex; survivor sex × radiotherapy 
(explores how the IQ of female survivors is affected by radiotherapy); radiotherapy × surgery; tumour 
type × radiotherapy; and time since diagnosis × radiotherapy (explores how the effect of radiotherapy 
differs over time, within GAM framework this results in separate curves for each level of 
radiotherapy). Within each set of GAMs, models were compared using the second-order Akaike 
Information Criterion (AICc [24, 25], a small sample size version of the standard AIC), where lower 
values indicate a better fitting model, in order to investigate the importance of the five interactions. 
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Results: 
Recruitment  
A potential maximum of 396 survivors were initially identified from the UK NRCT. Of these, 213 
people could be contacted via their GP and 118 took part, representing a 55% response amongst 
contactable survivors (Figure 1). A non-responder analysis demonstrated that demographic and cancer 
characteristics were similar between these 118 participants and those not participating (see 
Supplementary Materials in Carroll et al. [17]). Of the 118 participant survivors, 62 with a sibling 
who provided comparison data are reported on here. There was no indication of selection bias 
comparing suvivors without a recruited sibling (see Supplementary material). 
 
Survivors: Demographics and other characteristics 
Mean age at data collection was similar across females (35.6) and males (34.2) (t(52)=-0.545, 
p=0.588; r=0.075) as was years of education in excess of 10 years for females (3.1) and males (3.2) 
(t(42)=0.190, p=0.850; r=0.029). Twelve survivors had epilepsy and epilepsy history was unknown 
for one individual. 
 
Survivors: Diagnosis and treatment details 
Details of survivors’ age at diagnosis, tumour and treatment are in Table 1. There was little difference 
in the age at which males (39.6 months) and females (42.0) had been diagnosed (t(51)=-0.714; 
p=0.478; r=0.100). Tumour type did not affect age of diagnosis (F(2,59)=0.979, p=0.382). There was 
no difference between sexes in the proportion that received surgery (Fisher’s exact test: p=1.000; 
OR=1.127). For further analysis of variables associated with surgery, see Supplementary Materials. 
Astrocytoma was the most common tumour type (n=40) and included: fibrillary - 3; pilocytic - 28; 
NOS - 9. All the medulloblastoma (n=15) were recorded as ‘medulloblastoma, NOS’. The ‘Other’ 
group of tumours included: tumour cells - 1; subependymoma - 1; ‘ependymoma, NOS’ - 4; 
‘spongioblastoma, NOS’ - 1. 
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Age at diagnosis was not associated with whether radiotherapy was received (t(47)=-0.314; p=0.755; 
r=0.045). While not statistically significant (t(49)=-1.513; p=0.137), those who received radiotherapy 
had been diagnosed further into the past than those who had not (mean time since diagnosis (years): 
received radiotherapy=32.9, no radiotherapy=29.0), with a small to medium effect (r=0.212). There 
was little difference between sexes in the proportion who received radiotherapy (Fisher’s exact test: 
p=0.429; OR=0.589). Radiotherapy was more common for medulloblastomas (radiotherapy: 
medulloblastoma=87%, astrocytomas=48%, other=57%; Fisher’s exact test: p=0.025). Five survivors 
received chemotherapy in addition to radiotherapy. No participant had chemotherapy without 
radiotherapy. 
There was no significant difference in the proportion having surgery between those treated without 
radiotherapy (88%) and with radiotherapy (78%) (Fisher’s exact test: p=0.332; small to medium 
effect,OR=2.16). Around 45% (28/62) of survivors had radiotherapy and surgery.  
 
Demographic comparisons between survivors and siblings 
Descriptions of the 62 tumour survivors and their sibling comparators are given in Table 2.  
 
IQ comparisons between survivors and siblings 
Table 2 provides the VIQ and PIQ summary scores. The survivors’ VIQ scores were significantly 
lower on average than their siblings, by a mean difference of 15 points (p<0.001; r=0.655), and their 
PIQ scores by a mean difference of 19 points (p<0.001; r=0.670).  However, these mean group 
differences, as displayed in Supplementary Figure S1, include a wide range of differences in IQ scores 
between survivors and siblings. 
Supplementary Table 1 provides the IQ sub-test scores for survivors and siblings, demonstrating 
similar magnitudes of difference between sibling and survivor across all subtests. Unadjusted group 
IQ scores separated by sex are detailed in Supplementary Table S2.  
Mean VIQ and PIQ for different tumour types, along with sibling comparison IQ scores, are reported 
in Supplementary Table 3. For survivors, means of VIQ and PIQ by tumour type are similar. When 
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compared with their siblings, those with medulloblastomas score worse on VIQ (mean difference 
compared to siblings: medulloblastomas =-20.7, astrocytomas =-13.5 and ‘other’ tumour type =-14.7); 
however, this variation in difference is small (r≈0.7 versus r≈0.6).  
 
GAM: Verbal IQ 
The VIQ GAM with lowest AICc is reported in Table 3 and includes two interactions (survivor sex × 
sibling sex; survivor sex × radiotherapy). In this model n=61 (one participant has missing information 
about epilepsy), adjusted R²=0.32 and diagnostic plots suggest no problems with model fit.  
A plot of the smooth showing the effect of time since diagnosis on VIQ difference is shown in Figure 
2 (top): there is no significant evidence (p=0.5330) that this relationship differs from a horizontal line 
at zero (shown in the Figure by the confidence region around the smooth being centred on the red line, 
plotted at zero difference). The fitted smooth has estimated degrees of freedom (EDF) of 1.8, 
approaching a quadratic relationship (matching the gentle ‘u’ shape seen in the Figure 2 (top)). This 
model does not include an interaction between the smooth (i.e. time since diagnosis) and 
radiotherapy: this suggests little evidence for an effect of radiotherapy on VIQ difference changing 
over time (otherwise a model including this interaction would have had a lower AICc and 
subsequently been selected). 
Male survivors who had radiotherapy have VIQ scores that are on average 2.7 points closer to their 
siblings’ VIQ scores than male survivors who did not have radiotherapy (b=2.7; 95% CI: -8.5, 13.8; 
p=0.641). However, there is strong evidence (p=0.013) that in female survivors radiotherapy increases 
the VIQ difference between them and their siblings by around 19 points (-22+2.7≈19; b=-22.0; 95% 
CI=-38.7, -5.2).  
This analysis is repeated in the Supplementary Materials in a linear modelling framework, where the 
relationship between time since diagnosis and VIQ difference is restrictricted to a straight line. The 
model fits are very similar to those here and subsequent conclusions the same. 
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The Supplementary Materials also include a GAM as above, but extended to include two new 
covariates for additional years beyond compulsory education for survivors and siblings respectively. 
Due to missing data on these covariates, the sample size reduces to n=48. Conclusions are similar to 
the above primary analysis (time since diagnosis has no significant impact on VIQ; radiotherapy has a 
significant and larger impact on females). 
 
GAM: Performance IQ (PIQ) 
The PIQ GAM with lowest AICc is reported in Table 3 and includes one interaction (time since 
diagnosis × radiotherapy). In this model n=60 (one participant has missing information about epilepsy 
and another is missing PIQ), adjusted R²=0.41 and diagnostic plots suggest no problems with model 
fit. 
As there is an interaction between time since diagnosis and radiotherapy, a separate time since 
diagnosis relationship is estimated for those not receiving/receiving radiotherapy.  
Figure 2 (middle) shows the estimated effect of time since diagnosis on PIQ on the n=25 people who 
did not receive radiotherapy. A linear relationship (EDF=1) is estimated, in which the PIQ difference 
increases (gets better) as time since diagnosis increases. This relationship approaches significance 
(p=0.0822): the confidence interval region on Figure 2 (middle) only just encompasses the line (red) 
of no difference.  
Figure 2 (bottom) shows the estimated effect of time since diagnosis on PIQ on the n=35 people who 
did receive radiotherapy. A linear relationship (EDF=1) is estimated, in which the PIQ difference gets 
worse slightly as time since diagnosis increases. This relationship is not significant (p=0.5235): the 
confidence interval region on Figure 2 (bottom) is just off-centre of the line (red) of no difference. 
Radiotherapy is associated, on average, with a significant (p<0.001) and sizeable (r=0.468) decrease 
(worsening) of 18 (b=-18.0; 95% CI: -27.7, -8.3) PIQ points (given the model parameterisation, this 
corresponds to the radiotherapy difference at approximately 31 years after diagnosis, the mean time 
since diagnosis). There is little evidence of this differing by sex, as the model does not include 
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survivor sex × radiotherapy (otherwise a model including this interaction would have had a lower 
AICc). 
This analysis is repeated in the Supplementary Materials in a linear modelling framework. As the 
estimated smooths are straight lines, the GAM and linear model are very similar, with the same 
conclusions. 
The Supplementary Materials also include a GAM as above, but extended to include two new 
covariates for additional years beyond compulsory education for survivors and siblings respectively. 
Due to missing data on these covariates, the sample size reduces to n=48. In contrast to the primary 
analysis above, there is no interaction between time since diagnosis and whether survivors receive 
radiotherapy. This difference is driven by two aspects of this secondary analysis which limit its wider 
applicability: firstly the reduced sample size leads to a loss of statistical power to detect interactions; 
and secondly, there is a differential missingness on additional years beyond compulsory education and 
radiotherapy treatment – 12% (3/26) among survivors not receiving radiotherapy, and 31% (11/36) 
among survivors who received radiotherapy. The differential missingness may induce a selection bias 
that we cannot quantify, and the loss of statistical power induces a model that averages across the two 
groups rather than producing group-specific estimates. As in the primary analysis above, radiotherapy 
significantly impacts on PIQ, but there is no evidence of a differential effect by sex. 
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Discussion 
This study investigated, in adult survivors of an early childhood PFT, effects on intellectual 
functioning of increasing time since tumour diagnosis. No previous studies of long-term 
neurocognitive outcomes of childhood PFT survivors have focused on the question investigated here: 
namely, is increasing time since diagnosis, continuing well into adulthood, associated with later 
changes in IQ. Intellectual functioning was assessed using the WASI index measures of VIQ and PIQ. 
In the absence of repeated IQ measures within individuals across time, in this study VIQ and PIQ 
were measured on a single occasion in a cohort of survivors between 18 and 53 years after their 
tumour was diagnosed. Siblings’ IQ provided an estimated proxy for what individual survivors’ IQ 
might have been had they not developed tumours.  
Results indicated that, compared to their siblings, older adult survivors of a childhood PFT did not 
have relatively lower VIQ and PIQ scores than younger adult survivors. However, relative IQ deficits 
did persist in adulthood, with the possible exception of PIQ scores in survivors who did not receive 
radiotherapy, in whom there was a trend towards a reduction in survivor-sibling PIQ difference with 
greater time since PFT diagnosis. Our results were broadly robust to the inclusion of covariates that 
measure educational levels (see Results – no improving trend for PIQ was found for survivors who 
did not receive radiotherapy, but this is likely driven by greater levels of missing data in the secondary 
analysis). Our data do not allow any conclusions to be drawn regarding the possible basis for 
differences between VIQ and PIQ over time. It may be relevant that in a recent study of children 
treated below the age of four years for a medulloblastoma, whose cognitive performance was assessed 
an average of 4.9 years after their surgery, it was noted that those who had received cranial spinal 
irradiation were particularly impaired on motor decision time [26]. Further research will be needed to 
establish the time course of the effect of radiotherapy on this aspect of cognitive performance and to 
address the question of whether it relates to longer-term differences between PIQ and VIQ outcomes. 
Our findings indicating that following a childhood PFT relative cognitive deficits tend to persist is in 
line with other studies that have undertaken longer-term follow-up in this clinical group. Schreiber et 
al. [27] noted that in male children followed for 5 years after surgery for a medulloblastoma, those 
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whose acute treatment had been associated with the development of posterior fossa syndrome had 
relatively more impaired cognitive performance at one year post-surgery than those who did not 
develop it. Many of those impairments were still present four years later, and in some cases declined 
further over the four years of follow-up. They concluded that early brain insult associated with 
posterior fossa syndrome may contribute to an acute decline in attention, processing speed, and 
working memory with very little recovery over time. They also concluded, given that most of their 
participants received lower-dose radiation, that posterior fossa syndrome was a greater predictor of 
neurocognitive impairment than low-dose radiation. Posterior fossa syndrome is reported in up to 
29% of those receiving surgery for medulloblastoma [28]. Whilst we do not have a figure for the 
prevalence of posterior fossa syndrome in the participants of the current study, it is likely to only have 
been present in a small proportion. Hence, whilst, like Schreiber et al. [27], we observed evidence 
suggesting the persistence across time of a range of cognitive deficits, in the population reported in 
the current study, it is unlikely that the explanation for this finding was the presence of a post-
operative posterior fossa syndrome.  
Considering findings from longer-term follow-up studies, in one of the few previous studies that have 
followed survivors treated for a PFT in childhood into adulthood, Reimers et al. [13] reported IQ in 
participants with a mean age of 21.7 years and a mean age at diagnosis of 8.3 years. They observed a 
significant correlation between full scale IQ and age at diagnosis but not between full scale IQ and 
age at follow-up. These findings suggests, in results compatible with those from the current study, that 
IQ does not change progressively with increasing time since diagnosis. However, the inferences to be 
drawn from their study are limited by the wider age-range at diagnosis of their participants and the 
much shorter period of follow-up into adulthood. Ellenberg et al. [11] examined adult cognitive 
outcomes in survivors of a childhood CNS malignancy. They observed a range of neurocognitive 
symptoms in adulthood, using a self-reported behavioural rating inventory, and did not examine 
potential effects of increasing intervals of time between original diagnosis and follow-up in 
adulthood. 
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Our results also showed that, regardless of time elapsed since tumour diagnosis, a history of receiving 
radiotherapy was associated with relatively greater lowering of VIQ scores in female survivors and 
greater lowering of PIQ scores in both male and female survivors. Including covariates for 
educational level led to the same conclusions. The association between a history of childhood 
radiotherapy and subsequent cognitive impairment has been much researched and reduced white 
matter integrity has been proposed as contributing to persisting deficits in neurocognitive function. 
This may particularly be the case given the role of white matter in cortical information processing and 
integration [29]. Links with damage to various white matter tracts have been reported [30, 31]. It has 
also been demonstrated recently that in addition to longer-term effects of radiotherapy on cognition, 
functional impairments in cognition and diffuse white matter changes may be detected as soon as 
three months after treatment with wider-field, cranial-spinal radiotherapy compared to local 
radiotherapy [32]. Those authors also noted however that their group who had received just surgery, 
or surgery with local radiotherapy did over a subsequent follow-up period of three years also 
experience cognitive decline, although of lesser magnitude than those who had received cranial-spinal 
radiotherapy. 
In a study that investigated white matter tract integrity in young adults a mean of 13 years after their 
brain tumour diagnosis, King et al. [31] reported an association between a history of radiotherapy, 
lower IQ at follow-up and disrupted white matter tract integrity. As noted by King et al. [31] the white 
matter disruption they detected could have reflected loss of white matter, delayed maturation of white 
matter, or individual vulnerability to neurotoxicity associated with the tumour or its management. The 
results of the present study, with data indicating a persisting detrimental effect of radiotherapy on IQ 
across participants who were assessed an average of 32.9 years after diagnosis, a considerably longer 
follow-up period than that reported by King et al. [31], suggests that of the possibilities proposed by 
King et al. [31], delayed maturation appears to be unlikely. 
The reasons for the sex differences in the pattern of IQ results in those who received radiotherapy are 
unclear. Whilst no sex differences in intellectual outcomes have been reported in some studies [7], 
other reports do suggest that females may be more likely to have more adverse neurocognitive 
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outcomes [33]. Ellenberg et al. [11], in a study of children and young people aged from 0-20 years 
when diagnosed with a central nervous system malignancy, reported that female sex predicted more 
impaired scores on two measures of self-reported neurocognitive outcome; Task Efficiency and 
Emotional Regulation scales, with small effect sizes. Ris et al. [15] on the other hand, in a study of 
children and young people aged 3-21 years with a medulloblastoma treated with radiotherapy and 
chemotherapy, found no effect of sex on intellectual outcome measured using WISC or WAIS IQ 
tests between 2 and 5 years after tumour diagnosis. Possible reasons for these differences in observed 
effects of sex on intellectual outcome may include treatments prevailing during the eras in which the 
participants were treated and the length of follow-up. The participants reported by Ris and colleagues 
were all treated after 1996 whilst those reported in the current study were treated between 1940 and 
1991. Given the efforts to reduce radiation doses that have been pursued over time, it is possible that 
those reported here had received larger and less focused doses at a young age. However, the higher 
average age of tumour diagnosis and shorter follow-up period reported by Ris et al. [15] may also 
underpin the absence of observations of greater female vulnerability to adverse effects on IQ. Our 
finding of greater cognitive impairment in female survivors following a period of follow-up of at least 
18 years, is congruent with the observation by Hudson et al. [34], in survivors of a wide range of 
cancers, that female survivors had a greater and steeper trajectory of decline in at least one health 
domain compared to their same sex sibling than did male survivors. It has also been noted that female 
survivors of acute lymphoblastic leukaemia are at increased risk for neurocognitive impairment, 
whether they received radiotherapy or chemotherapy [16]. There is also evidence that in non-cancer 
brain injury females may have worse outcomes that males [35, 36]. No specific mechanism 
underlying poorer cognitive outcomes in females after brain insult have been identified, though with 
respect to post-menarche females sustaining traumatic brain injury, it has been proposed that 
disrupted physiology of gonadal steroids, possibly through an effect on the anterior pituitary gland, 
may play a role [36]. 
In line with the North American Childhood Cancer survivor study, we chose to recruit a sibling 
comparison group, controlling for shared genetic and sociodemographic factors [37]. Previous 
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research has demonstrated that the degree of hereditability for general intellectual functioning (g) is 
estimated as around 50% [38]. 
There are several limitations to our study. It is not longitudinal: instead of following survivors over 
time to examine changes in intellectual functioning, a cross-sectional design was used in which 
participants had a single IQ assessment. This design is limited by the age-period-cohort problem [39] 
and cannot separate effects of age-group, periods and cohorts; so cannot determine whether IQ 
changes relate to survivor age or to changes in treatment practices from 1940 to 1991. Additionally, 
our primary analysis does not include covariates that measure educational level – a quantity known to 
correlate with IQ – due to levels of missing data. However, we have conducted secondary analysis to 
check how our conclusions are impacted by variables that measure educational level: results are 
comparable given the reduced sample size. 
Importantly, any study of treatment effects after follow-up periods of several decades will face the 
issue that treatment practices will have changed since the interventions were carried out. This does not 
invalidate the findings of the present study. First, this study provides information relevant to current 
adult survivors of an early childhood PFT, their families and clinicians, as to what may be expected 
with regard to cognitive performance during adulthood. Secondly, the current study provides a base 
for future follow-up studies of later cohorts of long-term survivors from clinical trials run during the 
1990s and 2000s and who are now in their 20s and 30s, and comparison of our findings with data 
from such future studies would address the question of whether or not the observed pattern of long-
term outcomes remain similar despite all the changes in treatment practices. 
Our cognitive data are limited to estimates of VIQ and PIQ, meaning we cannot draw conclusions 
regarding specific aspects of cognition that would be of interest, for instance, processing speed. 
However, it is important to note that alternative opportunities for follow-up over as long as 50 years 
are limited.  
Our observation that VIQ deficits, and PIQ deficits in those receiving radiotherapy, develop during 
childhood but persist, without further decline, in adulthood, suggests that the effects on intellectual 
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functioning take the form of a fixed injury that imposes itself on subsequent cognitive development, 
rather than an ongoing pathological process. This emphasises the importance of seeking early 
interventions to optimize cognitive function during the developmental period [40]. 
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Caption for Figures: 
Figure 1 Flowchart of recruitment. Adapted from Carroll et al. [17] 
Figure 2 GAM smooth estimates for the relationship between time since diagnosis (years), while 
adjusting for all other covariates in the model in Table 3, and: a) verbal IQ (VIQ); b) performance IQ 
(PIQ) among those with no confirmed radiotherapy; c) PIQ among those with confirmed radiotherapy. 
The PIQ model includes an interaction between the smooth and ratiotherapy, hence we have two 
smooths for PIQ (b) and c)). The y-axis represents the difference between survivors’ and their 
siblings’ IQ scores, however the difference shown must be combined with the effect of other 
covariates from Table 3 to be interpreted. Since survivor’s scores are, on average, lower than their 
siblings the difference in scores will be negative (survivor minus sibling will be less than zero); hence 
a positive smooth value indicates the difference is decreased (ie survivors IQs are improving by 
getting closer to that of their siblings). Each panel includes a rug plot, showing the contributing 
participants/observations. 
 
Caption for Supplementary Materials Figure: 
Figure S1 GAM smooth estimates for the relationship between time since diagnosis (years), while 
adjusting for all other covariates in the model in Table S5, and: a) verbal IQ (VIQ); b) performance IQ 
(PIQ). The y-axis represents the difference between survivors’ and their siblings’ IQ scores, however 
the difference shown must be combined with the effect of other covariates from Table S5 to be 
interpreted. Since survivor’s scores are, on average, lower than their siblings the difference in scores 
will be negative (survivor minus sibling will be less than zero); hence a positive smooth value 
indicates the difference is decreased (ie survivors IQs are improving by getting closer to that of their 
siblings). Each panel includes a rug plot, showing the contributing participants/observations. 
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Table 1: Survivor diagnosis and treatment information. SD=Standard deviation. 
Diagnosis/treatment attribute Statistics/N 
Age at 
diagnosis 
Months 
Mean= 40.5, 
median= 44.0,  
SD= 13.3,  
range= 4-59 
Time since 
diagnosis 
Years 
Mean= 31.3, 
median= 29.5,  
SD= 9.9,  
range= 18-53 
Tumour type 
Astrocytoma  40 
Medulloblastoma 15 
Other 7 
Radiotherapy 
 
Chemotherapy 
No confirmed treatment 26 
Confirmed radiotherapy 31 
Confirmed radiotherapy and chemotherapy 5 
Surgery 
No recorded surgery 11 
Biopsy only 1 
Palliative surgery 2 
Removal (unspecified type) of primary tumour 8 
Partial removal of primary tumour 18 
Total removal of primary tumour 22 
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Table 2: Differences between the 62 survivor and sibling pairings. Paired t-tests are used for 
comparing continuous variables between groups.  
 
    Survivors Siblings 
Survivor v. sibling  
(unadjusted) comparisons Attribute Mean SD Range Mean SD Range 
Sex: females n=24 - - n=36 - - 
Fisher's exact test,  
p=0.048, OR=0.459 
Employed n=39* - - n=48† - - 
Fisher's exact test,  
p=0.196, OR=1.89 
Age (months) at 
data collection 34.8 10.1 19-57 35.0 10.8 19-59 
t(61)=-0.502, Dif=-0.3 (95% 
CI=-1.4, 0.8), p=0.617, r=0.064 
Age 
(years; 
deciles) 
19-29 n=26 - - n=23 - - 
Fisher's exact test,  
p=0.714 
30-39 n=16 - - n=19 - - 
40-49 n=15 - - n=12 - - 
50-59 n=5 - - n=8 - - 
Years beyond 
compulsory 
education 
3.2‡ 2.2 0-7 4.3† 2.5 0-7 
t(47)=-3.013, Dif=-1.3  
(95% CI=-2.1, -0.4),  
p=0.004, r=0.402 
Verbal IQ 88.3 18.1 55-121 103.7 12.0 77-127 
t(61)=-6.774, Dif=-15.4  
(95% CI=-19.9, -10.8),  
p<0.001, r=0.655 
Performance IQ 91.1§ 20.3 55-129 110.0 12.3 83-134 
t(60)=-6.982, Dif=-19.1  
(95% CI=-24.6, -13.7),  
p<0.001, r=0.67 
 
*N=56; †N=59; ‡N=50; §N=61. One survivor could not complete PIQ sub-tests due to vision 
problems, and so has no corresponding PIQ score.
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Table 3: The fit of the generalised additive models (GAMs) relating Verbal IQ (VIQ) and Performance IQ (PIQ) difference (survivor IQ-sibling IQ) to 
the covariates. The “Sibling (corresponding) IQ” is sibling VIQ in the VIQ model and sibling PIQ in the PIQ model. Grey cells indicate terms not 
included in a model. Bold italics indicate a p-value<0.05. Fits of the smooths of time since diagnosis included in the models are shown in Figure 2. 
 
    VIQ (n=61; adjusted R²=0.32) PIQ (n=60; adjusted R²=0.41) 
Variable Categorical level b 95% CI P-value r b 95% CI P-value r 
Intercept - -18.9 -40.2 2.5 0.090 0.247 0.0 -23.8 23.7 0.997 0.000 
Age at diagnosis (months) - -0.2 -0.5 0.2 0.379 0.130 0.3 0.0 0.7 0.074 0.258 
Tumour type* 
Astrocytoma 4.2 -6.3 14.8 0.437 0.115 -3.0 -14.9 8.8 0.620 0.073 
Other 9.8 -4.9 24.5 0.199 0.188 -5.0 -22.1 12.2 0.572 0.083 
Radiotherapy† Confirmed radiotherapy 2.7 -8.5 13.8 0.641 0.069 -18.0 -27.7 -8.3 <0.001 0.468 
Epilepsy‡ Present -7.4 -17.6 2.8 0.160 0.205 -9.5 -21.2 2.2 0.117 0.227 
Surgery§ Confirmed surgery 15.4 3.8 27.0 0.013 0.357 4.3 -7.8 16.3 0.491 0.101 
Survivor sexǁ Female -2.6 -16.1 11.0 0.711 0.055 -16.8 -26.0 -7.5 <0.001 0.461 
Sibling sex¶ Different to survivor -7.5 -17.9 2.8 0.161 0.205 -4.1 -13.5 5.3 0.395 0.124 
Sibling (corresponding) IQ (centred) - -0.2 -0.6 0.2 0.368 0.133 -0.6 -1.2 0.1 0.078 0.254 
Sibling (corresponding) IQ² (centred) - 0.0 0.0 0.0 0.972 0.005 0.0 0.0 0.0 0.071 0.260 
Survivor× sibling sex Female:sib sex diff. inter. 18.8 0.7 37.0 0.047 0.287 - - - - - 
Survivor sex × radiotherapy Female:therapy interaction -22.0 -38.7 -5.2 0.013 0.353 - - - - - 
   
*'Medulloblastoma' taken as reference level. †`No confirmed treatment' taken as reference level. ‡'Absent' taken as reference level. 
§`No recorded surgery' taken as reference level. ǁ'Men' used as reference level. ¶'Same as survivor' taken as reference level. 
 
 
